NDAINJECTIONINJECTABLE
Approved
Jan 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALDOL (haloperidol decanoate) is a long-acting injectable antipsychotic approved since 1986 for treating schizophrenia in adults. It works as a dopamine D2 receptor antagonist, with secondary binding to alpha-1 adrenergic receptors. The decanoate formulation provides extended therapeutic coverage, reducing dosing frequency compared to immediate-release haloperidol.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team consolidation and focus shift to managed decline or niche positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the ED: A RCT
Started Jun 2013
0Migraine HeadachesNauseaRestlessness
To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
Started Apr 1987
30 enrolled
Psychosis
Career Relevance
Working on HALDOL decanoate offers limited long-term career growth given LOE-approaching status and zero linked job postings, making this a defensive/maintenance role rather than growth opportunity. Professionals should expect smaller teams, focus on generic transition planning, and potential portfolio consolidation within Johnson & Johnson's psychiatry division.
Worked on HALDOL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.